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Background: Paroxetine has been demonstrated to undergo gestation related reductions in 22 
plasma concentrations, to an extent which is dictated by the polymorphic state of CYP 2D6. 23 
However knowledge of appropriate dose titrations is lacking.  24 
Methods: A pharmacokinetic modelling approach was applied to examine gestational changes 25 
in trough plasma concentrations for CYP 2D6 phenotypes, followed by necessary dose 26 
adjustment strategies to maintain paroxetine levels within a therapeutic range of 20-60 ng/mL.  27 
Key Findings: A decrease in trough plasma concentrations was simulated throughout gestation 28 
for all phenotypes.  A significant number of ultra-rapid (UM) phenotype subjects possessed 29 
trough levels below 20 ng/mL (73-76 %) compared to extensive-metabolisers (EM) (51-53 %).  30 
Conclusions: For all phenotypes studied there was a requirement for daily doses in-excess of 31 
the standard 20 mg dose throughout gestation. For EM, a dose of 30 mg daily in trimester 1 32 
followed by 40 mg daily in trimesters 2 and 3 is suggested to be optimal.  For poor-metabolisers 33 
(PM) a 20 mg daily dose in trimester 1 followed by 30 mg daily in trimesters 2 and 3 is 34 
suggested to be optimal.  For UM, a 40 mg daily dose throughout gestation is suggested to be 35 
optimal.  36 
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1. INTRODUCTION 40 
Depression in pregnancy is a serious and prevalent condition with incidence rates as high as 20 41 
% [1]. Selective serotonin reuptake inhibitors (SSRIs) include antidepressants such as 42 
citalopram, fluoxetine, sertraline, paroxetine and fluvoxamine. Paroxetine is used to treat 43 
several conditions including major depressive disorder, social anxiety disorder, posttraumatic 44 
stress disorder, panic disorder, obsessive-compulsive disorder and anxiety disorder [2, 3]. 45 
Paroxetine has been given a category D banding by the FDA because of its increased risk of 46 
causing birth defects when taken during the first trimester, in addition to being associated with 47 
neonatal withdrawal syndrome when administered later in pregnancy [4]. Nevertheless, the 48 
potential harms of using paroxetine during pregnancy should be weighed carefully against the 49 
potential for serious risks of untreated maternal depression.  This is particularly important given 50 
that recent reports in the UK have suggested that 1 in 25 women (aged 20-35 years) who die 51 
by suicide, do so during the perinatal periods (conception-pregnancy and post-natal) [5].  And 52 
further, that poor mental health during gestation is a highly correlated with poor mental health 53 
postnatally [6]. 54 
Paroxetine is primarily metabolised by Cytochrome P450 2D6 (CYP 2D6) and to a lesser extent 55 
(but equally important) by CYP 3A4, with minor roles for CYP 1A2, C219 and 3A5 [7].  56 
Further, paroxetine is also a mechanism-based inhibitor of CYP 2D6 [8, 9], which results in a 57 
significant decrease in clearance under multiple-dosing (steady-state) conditions [10]. Further, 58 
several studies have noticed an apparent increase in the activity of CYP 2D6 during gestation 59 
which results in an approximate 50 % decrease in paroxetine plasma concentrations compared 60 
to pre-pregnancy levels [3, 11-15]. However, perhaps complicating the use of paroxetine during 61 
gestation, is the fact that CYP 2D6 is extensively polymorphic with at least a 7-fold difference 62 
in the median total clearance between the extensive metabolism (EM) and poor metaboliser 63 
(PM) phenotypes [10, 16].  Furthermore, the therapeutic window was assumed to be in the 64 
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range of 20-60 ng/mL [17, 18]. However, therapeutic blood concentrations for paroxetine can 65 
range from 10 ng/mL to 120 ng/mL [19], with toxicity reported to commence at approximately 66 
350 ng/mL [20]. 67 
There are no well-controlled, large scale reliable studies of paroxetine use throughout gestation.  68 
However, the clinical toxicology database TOXBASE® (https://www.toxbase.org) [21],  from 69 
the National Poisons Information Service Unit has published guidance for paroxetine use 70 
throughout pregnancy and suggest that paroxetine can be continued where an SSRI is 71 
considered clinically necessary and where paroxetine has been found to be the only effective 72 
agent.  Further, the risks of continuing must be weighed against the possible negative outcomes 73 
associated with relapse [22].  It is important to consider the risks associated with any relapse 74 
as well the risk of relapse itself and recommendations are to use the lowest effective dose and 75 
for clinicians to follow this advice without risking relapse [22].  With this in mind, it is 76 
important that clinicians are aware of likely gestation-related variation in paroxetine levels 77 
[23]. 78 
In the context of post-natal period, paroxetine has been reported to lead to neonatal withdrawal 79 
syndrome, particularly persistent pulmonary hypertension of the new-born (PPHN) when 80 
paroxetine is used beyond 20 weeks gestation, but not amongst infants of mothers who used 81 
the drug prior to eight weeks [24].  However, this risk is thought to be small for the SSRI group 82 
as a whole [25]. 83 
Given that poor mental health during gestation is a highly correlated with poor mental health 84 
postnatally [6], the benefit of therapy should be weighed against the potential risk of cessation 85 
of therapy and the associated consequence for the mother and child [6, 26].  However, the 86 




In light of the paucity in pharmacokinetic data for paroxetine during gestation, we have, for the 89 
first time, applied the concept of pharmacokinetics-based virtual clinical trials dosing to 90 
elucidate possible dose adjustments that could be implemented in both EM and polymorphic 91 
CYP 2D6 subjects throughout gestation.  The primary aim of this study was to use the 92 
principles of mechanistic pharmacokinetic modelling and virtual clinical trials to: (i) elucidate 93 
the causative effects of this decrease in plasma paroxetine levels during gestation and (ii) to 94 
provide a clinically relevant dosing adjustment strategy that could be implemented to maintain 95 
plasma paroxetine levels during gestation, when taking into consideration the CYP 2D6 96 
phenotype status patients.   97 
 98 
2. METHODS  99 
The physiologically-based pharmacokinetic (PBPK) modelling tool Simcyp was utilised to 100 
conduct virtual clinical trials simulations in subjects (Simcyp Ltd, a Certara company, 101 
Sheffield, UK, Version 17). For studies in Step 1, simulations incorporated mixed genders 102 
(50:50), with studies in Step 2-4 utilising females only.  A four-stage workflow approach was 103 
applied for the development, validation and simulation studies with paroxetine (Figure 1). 104 
Adaptations to both the paroxetine ‘compound file’ and the Pregnancy ‘population group’ were 105 
made and described below. 106 
2.1 Step 1: Validation of paroxetine 107 
Within the virtual clinical trial simulator Simcyp, the ‘healthy volunteer’ (HV) population 108 
group was used to simulate ‘non-pregnant’ females as a baseline, with the ‘pregnancy’ 109 
population group utilised for all gestational studies.  The pregnancy population group was 110 
developed by Simcyp, to included necessary gestational dependant changes in physiology, such 111 
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as blood volume and organ/tissue perfusion and enzyme/protein expression thought to play a 112 
role in altering the pharmacokinetics of drugs [27-30].  113 
 114 
Paroxetine has been previously developed by Simcyp and incorporated into the Simcyp 115 
simulator [7]. However, to account for the impact of physiological alterations during gestation 116 
on paroxetine pharmacokinetics, a modification to the prediction of the volume of distribution 117 
at steady-state (Vss) was required, from a pre-set minimal-PBPK model to a full-body PBPK 118 
distribution model. This required the application of a Weighted Least Square (WLS) approach 119 
and the Nelder-Mead minimisation method to the calculation of Vss from a tissue-partition 120 
coefficient scaler (Kp scalar) [31].  The pharmacokinetics parameters used for paroxetine 121 
model are detailed in Supplementary Materials (Table S1).    122 
Validation of the revision made to the paroxetine compound file employed three single dose 123 
studies and two multiple dose studies: (i) 28 male healthy volunteers (18-50 years old) dosed 124 
a single oral dose of 20 mg [32]; (ii) 9 healthy male subjects administered a single 20 mg oral 125 
dose of paroxetine [33]; (iii) 12 healthy volunteers aged between 20-35 years old (9 males, 3 126 
females) administered a 20 mg single dose of paroxetine [34]; (iv) 28 healthy volunteers 127 
administered a 20 mg daily for 13 days, with sampling on days 12 and 13 [35]; (v) 7 healthy 128 
males administered a 20 mg oral dose of paroxetine daily for 3 days, with sampling on day 1 129 
and 3 [36]. 130 
Simulation trial designs were run to match clinical studies used in validation.  131 
 132 
2.2 Step 2: Validation of paroxetine during gestation 133 
Paroxetine plasma concentrations have been reported during gestation from a retrospective 134 
analysis of therapeutic drug monitoring services in Norway [3], consisting of 29 serum drug 135 
concentrations during pregnancy and 31 drug concentrations at baseline (non-pregnancy 136 
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females) obtained from 19 women taking an oral dose of 20 mg daily. This data was extracted 137 
and utilised as ‘observed’ data for validation purposes. The Simcyp Pregnancy population 138 
group was adapted to incorporate CYP 2C19 activity modifications during gestation, details of 139 
which can be found in the Supplementary Materials Section 1.  Further, the optimised Vss 140 
predicted from Step 1 was applied here, which was allowed to alter in line with maternal 141 
physiological changes during gestation. 142 
In simulating paroxetine pharmacokinetics during gestation, a 38-week trial design was 143 
utilised, with simulations conducted using a 3x10 trial design with a daily oral dose of 20 mg 144 
daily for all subjects. Data was collected over the final 24 hours of every fifth week. The trial 145 
design was also replicated for healthy volunteer population of non-pregnant females (baseline) 146 
dosed under the same dosing strategy for comparison. Furthermore, changes in AUC and total 147 
in-vivo clearance were quantified during gestation.  148 
 149 
2.3 Step 3: Phenotype simulation 150 
To assess the impact of CYP 2D6 phenotypes on maternal paroxetine plasma concentrations, 151 
data was extracted from an observational cohort study in 74 pregnant women aged from 25 to 152 
45 years who used paroxetine during pregnancy and where data was reported for gestational 153 
weeks 16–20, 27–31 and 36–40 [37]. The study included data from 43 extensive metabolisers 154 
(EM), 5 poor metabolisers (PM) and 1 ultra-rapid metaboliser (UM). 155 
Simulations were conducted using a 10x10 trial design at GW 20, 30 and 38, with EM, UM 156 
and PM populations dosed 20 mg daily during gestation, and compared to results obtained from 157 





2.4 Step 4: Dose adjustment during gestation 161 
In order to identify the requirement for a dose adjustment during gestation, we examined the 162 
impact of dose escalation on paroxetine plasma concentrations. Doses were escalated in 5 mg 163 
increments every 3 days to 15-50 mg daily doses during gestation, with trough plasma 164 
concentrations analysed for the final day of each trimester.  165 
Data was collected and reported for the EM, PM and UM phenotype. The percentage of 166 
subjects with trough plasma concentrations below 20 ng/mL and above 60 ng/mL were 167 
quantified for each trimester and each phenotype. 168 
 169 
2.5 Predictive performance 170 
For all simulations in steps 1-3, a prediction of a pharmacokinetic metric to within two-fold 171 
(0.5-2.0 fold) of that published clinical data was generally accepted as part of the ‘optimal’ 172 
predictive performance [38-40]. 173 
 174 
2.6 Visual predictive checks 175 
Model predictions in step 1-3 were compared to clinical studies using a visual predictive 176 
checking (VPC) strategy [41]. In this approach, the predicted mean/median and 5th and 95th 177 
percentiles of the concentration–time profiles (generated from Simcyp) were compared against 178 
the observed data for any validation data sets.  The prediction was assumed to be valid when 179 





2.7 Data and statistical analysis 183 
All observed data obtained from clinical studies were extracted using WebPlotDigitizer v.3.10 184 
(http://arohatgi.info/WebPlotDigitizer/). Statistical analysis was conducted using a non-185 
parametric Kruskal-Wallis with a Dunn’s multiple comparison post-hoc test.  Statistical 186 
significance was confirmed where p < 0.05 was determined.  All statistical analysis was 187 
performed using GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla 188 
California USA, www.graphpad.com). 189 
 190 
3. RESULTS 191 
3.1 Step 1: Validation of a revised paroxetine full-body PBPK model 192 
A validated paroxetine model, developed and incorporated into the Simcyp Simulator, was 193 
utilised with adaptations to include a full-PBPK model for determination of appropriate Vss 194 
and to model physiological changes during gestation.  The model was validated against a range 195 
of published clinical studies using the Simcyp healthy volunteer population group. For all 196 
single dose studies (Figure 2A and 2B) and multi-dose studies (Figure 2C), the simulated 197 
plasma concentration-time profiles were successfully predicted to within the observed range 198 
for each study and model-predicted tmax, Cmax, and AUC were predicted to within 2-fold of the 199 
reported parameters for each study, confirming successful validation (Table 1).  200 
 201 
3.2 Step 2: Validation of paroxetine during gestation 202 
Model predicted plasma concentrations during gestation overlapped with the range of 203 
observations reported [3] during the entire period of gestation (Figure 3). The mean at 204 
baseline, 24.05 ng/mL ± 15.45 ng/mL, decreased for trimesters 1 (week 5: 21.51 ng/mL ± 205 
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12.93 ng/mL), 2 (week 20: 18.09 ng/mL ± 11.72 ng/mL) and 3 (week 30: 17.16 ng/mL ± 206 
11.05 ng/mL), with a statistically significant decrease from week 15 onwards to week 35 (p < 207 
0.05). 208 
Given the polymorphic nature of the primary metabolic pathway of paroxetine (CYP 2D6), the 209 
changes in both clearance and AUC were further assessed during gestation for EM, PM and 210 
UM phenotype subjects within the heterogeneous healthy volunteer population generated by 211 
Simcyp (default Caucasian frequencies: EM: 86.5 %, PM: 8.2 % and UM: 5.3 %). 212 
For both EM and PM, statistically significant differences in the AUC were apparent from 213 
gestational week (GW) 15 (EM) and GW10 (PM) onwards, respectively and GW25 for UM 214 
when compared to baseline subjects (Figure 4) (Supplementary Materials: Table S2 and S3). 215 
For CL, statistically significant differences for both EM and PM were evident from GW10 216 
onwards and week 20 for UM.  (Supplementary Materials: Table S2 and S3) (Figure 4). 217 
For UM the AUC and CL demonstrated a 70-80 % decrease and 450-480 % increase in 218 
trimester 3 when compared to baseline, respectively (Figure 4). This is in comparison to EM 219 
where a 19-22 % decrease and 16-18 % increase in AUC and CL were noted from baseline, in 220 
trimester 3, respectively (Supplementary Materials: Table S2) (Figure 4). 221 
 222 
  223 
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3.3 Step 3: The impact of CYP 2D6 phenotypes on paroxetine levels during gestation  224 
The effect of CYP 2D6 phenotypes on maternal paroxetine plasma concentrations during 225 
pregnancy were subsequently directly explored. Paroxetine plasma concentrations have 226 
previously been reported in CYP 2D6 phenotyped subjects [37].  To validate the ability of the 227 
model of recapitulate the impact of CYP 2D6 phenotypes (EM, PM and UM) on paroxetine 228 
levels,  we compared model predictions of uniform singular phenotype population to those 229 
reported [37].  For EM, the predicted range of paroxetine plasma concentration (determined 230 
from the range of simulated maximum and minimum values), where within the range reported 231 
(Figure 5A).  For PM (Figure 5B) and UM (Figure 5C), despites there being a limited number 232 
of reported values plasma concentration measurements available, predicted paroxetine vales 233 
were generally within or spanning the range reported [37] (Figure 5).  234 
Within each phenotype, a decrease in both peak and trough concentrations were noted (Table 235 
2), with the UM phenotype resulted in a significant number of subjects possessing trough levels 236 
below 20 ng/mL (73-76 %) compared to EM (51-53 %) (Table 2). 237 
 238 
3.4 Step 4: Paroxetine dose optimisation 239 
To identify appropriate dose adjustments during gestation for CYP 2D6 phenotypes, the 240 
number of subjects with trough concentration below 20 ng/mL and above 60 ng/mL were 241 
quantified over the dosing range of 15-50 mg daily.   242 
In all phenotypes studies (EM, PM and UM), the daily dose required was in excess of the 243 
standard 20 mg/day throughout gestation.  The choice of optimal dose was based around 244 
ensuring a balance of a low percentages of subjects with plasma levels below 20 ng/mL or 245 
above 60 ng/mL.  In order to accomplish this, a suggested indicator of 20 % was used to ensure, 246 
13 
 
where possible, as many subjects as possible had trough concentration above 20 ng/mL in 247 
addition to being below 60 ng/mL (Figure 6). 248 
For EM, a dose of 30 mg daily in trimester 1 followed by 40 mg daily in trimesters 2 and 3 is 249 
suggested to be optimal.  For PM a 20 mg daily dose in trimester 1 followed by 30 mg daily in 250 
trimesters 2 and 3 is suggested to be optimal.  For UM, a 40 mg daily dose throughout gestation 251 
is suggested to be optimal 252 
In determining the appropriate dose, the 40-50 mg/d doses resulted in the highest individual 253 
trough concentration in the range of 200-300 ng/mL for the trial group (Supplementary 254 
Materials: Table S4). 255 
 256 
4. DISCUSSION 257 
Depression is far more prevalent in women than men [42, 43], and is the leading cause 258 
of disability worldwide [44].  Furthermore, the prevalence of depression during pregnancy is 259 
thought to be in excess of 10 % [45], however the use of mental health services by pregnant 260 
women is low, approximately 14 %, when compared to non-pregnant women, approximately 261 
25 % [46].  The use of pharmacological treatment for mental health disorders during pregnancy 262 
is governed by balancing the risk to the foetus alongside the risk of relapse in the mental health 263 
of the mother.  264 
Confounding treatment however, are gestation related alterations in maternal physiology which 265 
can impact upon the pharmacokinetics of drugs. These alterations include the reduction in 266 
intestinal motility, increased gastric pH, increased cardiac output, reduced plasma albumin 267 
concentrations, and increased glomerular filtration rate [47]. However, the consequences of 268 
such alterations are often difficult to ascertain in controlled trials for obvious ethical reasons, 269 
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which leaves prescribers to empirically treat pregnant patients according to their understanding 270 
of the changes in biochemical and physiologic functions [14].  271 
However, to assess the potential impact of pregnancy on antidepressant therapy, the use of 272 
robust and validated mechanistic pharmacokinetic models provides an opportunity to 273 
prospectively assess the potential changes in a drugs pharmacokinetics to support medicines 274 
optimisation.  275 
Paroxetine is primarily metabolised by CYP2D6 and to a lesser extent by CYPs 3A4, 1A2, 276 
C219 and 3A5 [7].  Further, paroxetine is also a mechanism-based inhibitor of CYP 2D6 [8, 277 
9], which results in a significant decrease in clearance under steady-state conditions [10]. The 278 
use of paroxetine duration gestation is complicated by the fact that several studies have 279 
noticed an apparent increase in the activity of CYP 2D6 during gestation [11-15], with an 280 
associated decrease in paroxetine plasma concentration during gestation, by up to 50 %, in 281 
comparison to non-pregnant females [3].  282 
Given the lack of more detailed clinical studies examining this phenomenon, for the first time 283 
this study applied the principle of pharmacokinetic modelling to prospectively assess the use 284 
of paroxetine in pregnancy population groups and attempted to relate changes in plasma 285 
concentrations during gestation to a potential therapeutic window region.  The Simcyp 286 
pregnancy PBPK model has been utilised by our group and others for prediction of the impact 287 
of changes in plasma concentrations associated with gestation [28, 31, 48], however this is the 288 
first time it has been utilised in the context of paroxetine. 289 
The development of the model utilised an existing, validated and published model of 290 
paroxetine within the Simcyp Simulator, with minor modification to allow it to be used in the 291 
context of pregnancy, particularly to account for the impact physiological changes in 292 
gestation on paroxetine pharmacokinetics.  This was accomplished by utilising paroxetine 293 
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within a full-body physiologically based pharmacokinetics (PBPK) model.  This adaptation 294 
required validation against single and multiple dose studies in non-pregnant subjects (Step 1) 295 
followed by pregnant subjects (Step 2). Resulting predictions in non-pregnant subjects, were 296 
within 2-fold of those reported along with appropriate VPC confirming population level 297 
variability in plasma concentrations (Figure 2) were appropriately predicted in relation to the 298 
clinically reported variability (Table 1). 299 
There is currently a paucity of pharmacokinetics data examining the impact of 300 
gestation on paroxetine plasma concentrations.  To our knowledge, Westin et al [3] is the 301 
only publication (to date) containing paroxetine plasma concentrations sampled in patients 302 
throughout gestation.  This was therefore used as the basis for validating the paroxetine 303 
pregnancy PBPK model.  Simulations were conducted for the entire gestation period (38 304 
weeks) and sampling and quantification conducted on the final day of each week for every 5th 305 
week during gestation (Weeks 0-35) (Figure 2).    In non-pregnant subjects (‘baseline’), the 306 
predicted plasma concentrations (24.05 ng/mL ± 15.45 ng/mL) were within 2-fold of those 307 
reported by Westin et al [49] (33.5 ng/mL) (Table 2) and further spanned across a similar 308 
range of reported values. Westin et al [3] reported a 12 %, 34 % and 51 % decrease in mean 309 
plasma concentration at for trimesters 1-3, respectively.  Using the PBPK model we 310 
demonstrated a similar decrease of up to 30% by trimester 3 (Figure 2).   311 
In order to understand the rationale for the decrease in paroxetine plasma levels during 312 
gestation, we further assessed changes in total (in-vivo) clearance and AUC.  This was 313 
demarked for the CYP 2D6 phenotype of each subject. In all phenotypes, the clearance 314 
increased during gestation, which mirror the increase in 2D6 activity reported during gestation 315 
[14], with the greatest difference in clearance occurring in trimester 3 (Supplementary 316 
Materials: Table S2). This increase in clearance would therefore reduce the overall 317 
bioavailability within subjects, as demonstrated by the statistically significant difference in the 318 
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AUC in trimester 3 for all phenotypes (Supplementary Materials: Table S2). Within each 319 
phenotype, the UM subjects demonstrated the greatest difference in both clearance and AUC 320 
during gestation. 321 
The decrease in plasma concentrations noted in our study concurs with previous reports [14, 322 
37], and may be associated with temporal changes in CYP 2D6 expression (induction) noted 323 
throughout gestation [15]. Ververs [37] reported an increase in PM plasma concentration [37] 324 
during gestation, which is in contrast to the reduction modelled within our studies. However, 325 
the number of PM subjects in their study, n=1, is low making it difficult to extrapolate to a 326 
larger cohort of PM subjects in a generalised fashion. 327 
Given the importance of the phenotype of the subject on gestational paroxetine levels, 328 
we next explored the ability of the model to correctly capture phenotype levels and also to 329 
examine the tough levels in the context of the therapeutic window.  Paroxetine plasma 330 
concentrations have previously been reported in CYP 2D6 phenotyped subjects [37], of which 331 
the EM, PM and UM were investigated using uniform singular phenotype populations.  Ververs 332 
reported single point levels which were sampling at non-specific intervals post-dosing [37] and 333 
therefore comparison were made to Cmax and Cmin levels in each subject simulated in our 334 
studies.  For both EM (Figure 5A) and PM (Figure 5B), model predicted levels spanned the 335 
range of reported levels across gestational weeks (Figure 5).  For the UM phenotype 336 
population, only 3 observed samples were available across gestation (Figure 5C). Although the 337 
predicted levels spanned some of the predicted levels, the lack of UM data precludes a full 338 
comparison to be made (Figure 5).  339 
For the PM phenotype, as a result of a loss of function alleles, gestational changes in paroxetine 340 
pharmacokinetics would be primarily governed by maternal physiological alterations or 341 
alternative clearance pathways, e.g. CYP 3A4, whose activity is known to increase during 342 
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gestation [50], rather than direct changes in CYP 2D6 expression.  Thus, the combined impact 343 
of minimal CYP 2D6 mediated clearance (in PM phenotypes), but enhanced CYP 3A4 344 
clearance due to gestational induction, may result in a potential net minimal changes in plasma 345 
levels during gestation [48].   346 
To assess the potential impact of these polymorphic subjects on possible sub therapeutic 347 
levels, we quantified the percentage of subjects with trough concentration below the lower 348 
therapeutic window (20 ng/mL).  The UM group demonstrated significantly larger percentages 349 
below 20 ng/mL when compared to the EM group (Supplementary Materials: Table S4), > 70 350 
% from week 20 onwards.  Whereas for the PM group, this remained at 34 % from week 20 351 
onwards. Given this variability, we next examined how a dose adjustment could be made for 352 
EM, PM and UM subjects throughout gestation. 353 
For all phenotypes studies (EM, PM and UM), there was a requirement for daily doses 354 
in-excess of the standard 20 mg dose throughout gestation.  Whilst there is some uncertainty 355 
as to the upper most limit of the therapeutic window (60-350 ng/mL) [19, 20, 51], the lower 356 
window was used as a reference point for dose optimisation with trough levels.  357 
For EM, a dose of 30 mg daily in trimester 1 followed by 40 mg daily in trimesters 2 and 3 is 358 
suggested to be optimal.  For PM a 20 mg daily dose in trimester 1 followed by 30 mg daily in 359 
trimesters 2 and 3 is suggested to be optimal.  For UM, a 40 mg daily dose throughout gestation 360 
is suggested to be optimal 361 
The PM phenotype has been shown to require more frequent switches and dose modification 362 
[52] due to an increase in the frequency and severity of associated  concentration-dependent 363 
adverse effects [53], resulting in an approximate 4-fold increase in the risk of discontinuation 364 
during pregnancy [54]. This makes appropriate dose modification difficult in women who are 365 
already experiencing adverse effects during gestation, such as nausea from morning sickness 366 
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in addition to nausea as an SSRI adverse drug reaction.  Further, for the UM group, this cohort 367 
would be at greater risk of sub-therapeutic paroxetine plasma concentration without a dose 368 
adjustment, resulting in an increase in depressive symptoms, as has been recently noted in a 369 
retrospective analysis of phenotyped pregnant women taking anti-depressant drugs during 370 
gestation [54].  371 
The outcomes of the dose optimisation study identified that a dose increase would be 372 
required throughout gestation, irrespective of the phenotype.  With EM requiring an increase 373 
to 30-40 mg daily, PM 20-30 mg daily and UM 40 mg daily.  In all of these cases, the 374 
percentage of subjects with sub-therapeutic concentrations (<20 ng/mL) would be less than 20 375 
%.  Post-natal dose tapering would be required to return maternal plasma levels to those in the 376 
pre-natal period.  Whilst the capability of simulating the return of maternal physiology to the 377 
pre-natal period is not possible within Simcyp, Nagai et al (2013)[55] have suggested a tapering 378 
dose decrease of 10 mg per week commenced before delivery, based upon transplacental 379 
paroxetine transfer and pharmacokinetic modelling, may be effective in reducing the incidence 380 
of withdrawal symptoms in the neonate and mother.  However, paroxetine has a very short 381 
half-life (compared to other SSRIs) and discontinuation phenomena are a concern. Clinicians 382 
should be encouraged to be alert for these during dose tapering as they would in any other dose-383 
reduction phase with SSRIs. 384 
It should be noted that given paroxetine is administered orally, changes in gestational gastric 385 
physiology such as delayed gastric emptying [56, 57] and alterations in gastric pH [58] may 386 
alter the absorption of paroxetine ab orally, studies have demonstrated that given paroxetine is 387 
completely absorbed [59, 60], changes in GI-physiology during gestation are likely to have a 388 
minimal effect.  Further, paroxetine oral absorption is unaffected by changes in gastric pH [61] 389 
negating the potential impact of changes in paroxetine ionization and dissolution ab orally 390 
during gestation.  However gestational related changes in material GI-physiology are not 391 
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currently incorporated in the Simcyp Simulator utilised within this study.  Nevertheless, the 392 
utilising of robust validation approaches allowed for the pragmatic assessment of the need for 393 
dose adjustment during gestation, however further confirmatory clinical studies are warranted 394 
to confirm the results presented within this study.  395 
5. CONCLUSION 396 
The decision to continue or withdraw antidepressants during pregnancy is challenging when 397 
considering the paramount importance of both maternal and neonatal health.  The prescriber 398 
must actively decide whether the benefit of continuing treatment outweighs any risk of the drug 399 
to the developing embryo/foetus.  If treatment is continued throughout pregnancy, the changes 400 
in maternal physiology should be considered in dosing strategies.  With paroxetine, this is 401 
further confounded given its susceptibility to CYP 2D6 polymorphism.  Based upon modelling 402 
studies, our findings suggest that optimisation of paroxetine during pregnancy requires dose 403 
increase when compared to non-pregnant patients, driven by changes in tissue physiology and 404 
its impact on the volume of distribution, in addition to gestation related alterations in CYP 405 
isozyme abundance. For UM phenotypes, at least a doubling in the dose is required to provide 406 
a plasma concentration within the therapeutic range. 407 
 408 
Although there is no requirement for genetic testing prior to initiation for SSRIs, our approach 409 
highlights the opportunity for pharmacokinetics to bring precision dosing into clinical practice.  410 
Pre-emptive genotyping may be an approach to support precision dosing in pregnancy to 411 
optimise drug therapy and to reduce the risk of relapse due to inadequate dosing.  412 
However, further studies are required to assess both the extent of this gestational change on 413 
plasma concentrations and any associated requirement for dose adjustment, in addition to also 414 
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identifying a more accurate therapeutic range to more precisely define the necessary dose 415 
adjustments. 416 
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List of Figures 590 
 591 
Figure 1.  A four-stage workflow based approach to paroxetine modelling 592 
 593 
Figure 2.  Simulated paroxetine plasma concentrations following single and multiple 594 
dosing.  595 
(A) Single 20 mg oral dose of paroxetine [32, 34]; (B) Single oral 20 mg dose with observed 596 
data presented as multiple sampling [33]; (C) Multiple daily 20 mg oral dose [35, 36]. Solid 597 
lines represent mean predicted concentration-time profile with dotted lines representing 5th and 598 
95th percentile range. Solid circles represent observed clinical data from each study with error 599 
bars indicating standard deviation. 600 
 601 
Figure 3.  Simulated paroxetine plasma concentrations during gestation  602 
Paroxetine plasma concentrations were simulated during gestation (n=30). Simulated 603 
concentrations represent post-dose trough concentrations (sampled at 24 hours after dosing) 604 
and collated at 5-week intervals over the gestation period (black open circles). Subjects were 605 
administered a 20 mg daily dose. ‘Baseline’ refers to non-pregnant females.  Red open circles 606 
represent observed (pooled) plasma concentrations obtained from a total of 19 subjects. Shaded 607 
regions between 20 ng/mL to 60 ng/mL represents the therapeutic window. 608 
 609 
Figure 4. Impact of gestation on paroxetine pharmacokinetics, demarked by CYP 2D6 610 
population phenotype status.  611 
31 
 
The impact of gestation on paroxetine (A) area under the curve (AUC) and (B) clearance at 612 
baseline (non-pregnant females) and during gestation. Data is demarked for the population 613 
(n=100) phenotype status with black circles representing EM, red circles representing UM and 614 
green circles represented PM.  Solid coloured line represents median value.  615 
 616 
Figure 5.  Simulated paroxetine plasma concentrations for CYP 2D6 polymorphs. 617 
Paroxetine peak (Cmax) and trough (Cmin) plasma concentration were simulated in CYP 2D6 618 
EM (A), PM (B) and UM (C) subjects at gestations week 20, 30 and 38. Simulations 619 
concentrations were compared to reported plasma concentration (red open circles) for each 620 
phenotype.   Blue circles: Cmin of each subject; green circles: Cmax of each subject. 621 
 622 
Figure 6. Phenotype-based dose optimisation of paroxetine during gestation.  623 
Paroxetine doses were escalated in 5 mg increments every 3 days to 15-50 mg daily does during 624 
gestation, with trough plasma concentrations analysed for the final day of each trimester in 625 
entirely EM, PM or UM pregnancy population groups.  The number of subjects with trough 626 
plasma concentration below 20 ng/mL (left panels) or above 60 ng/mL (right panels) are 627 
reported.   628 
  629 
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List of tables 630 
Table 1: Summary pharmacokinetics parameters from the single and multiple dose 631 
studies  632 
 633 
AUC= Area under the curve, Cmax = Maximum plasma concentration, tmax= time at maximum 634 
plasma concentration. Data represents mean (standard deviation). AUC: ng/mL.h; Cmax: 635 
ng/mL; tmax: h.  636 
 637 






Segura et al 
(2003)[33] 
AUC(0-24 h) 96.50 (65.90) 156.83 (138.69) 
Cmax 8.60 (5.50) 11.10 (8.87) 
tmax 5 (3-5) 3.9 (1.72) 
Yasui-Furukori et 
al (2007)[34] 
AUC(0-48 h)  127 (67) 230.3 (222.34) 
Cmax  6.5 (2.4) 11.10 (8.87) 
tmax 5 (4-10) 3.9 (1.71) 
Massaroti et al 
(2005)[32] 
AUC(0-120 h) 225.04 (291.91) 312.34 (347.90) 
Cmax  9.02 (8.82) 11.10 (8.87) 







Segura et al 
(2005)[36] 
AUC(0-8 h) [Day 1] 53.8 (26.7) 65.37 (53.52) 
AUC(0-8 h) [Day 8] 159.8 (49.8) 205.76 (104.80) 
Cmax [Day 1] 10.4 (4.8) 11.09 (8.87) 
Cmax [Day 8] 26.1 (7.1) 31.61 (15.18) 
tmax [Day 1] 3 (3–5) 3.87 (1.62) 
tmax [Day 8] 8 (3–8) 4.15 (0.83) 
33 
 
Table 2. Simulated paroxetine plasma concentrations during gestation 638 
 639 
Data represents mean (range). EM: extensive metabolises; PM: poor metabolisers; UM: 640 
ultrarapid metabolisers; Cmax: maximum plasma concentration; Cmin: minimum plasma 641 
concentration. 642 
  
Week Cmax (ng/mL) Cmin (ng/mL) 
Trough % < 20 
ng/mL (% subjects) 
EM 
20 39.875 (129.6-2.45) 19.63 (0.15-91.87) 51 
30 37.235 (2.01-122.28) 18.765 (0.14-87.64) 53 
38 36.56 (1.88-120.04) 18.82 (0.15-86.16) 53 
PM 
20 46.535 (18.95-147.25) 25.225 (6.06-109.49) 34 
30 43.77 (17.62-139.78) 24.345 (6-105.09) 34 
38 42.85 (17.21-136.98) 24.435 (5.99-103.05) 34 
UM 
20 34.4 (0.55-110.91) 12.465 (0.04-73.3) 73 
30 31.69 (0.45-103.66) 11.665 (0.04-69.13) 76 
38 30.84 (0.42-102) 11.985 (0.04-68.22) 76 
